健帆生物(300529.SZ):2024年淨利潤同比增長87.91% 擬10股派8元
格隆匯4月15日丨健帆生物(300529.SZ)公佈2024年年度報告,2024年度,公司實現營業收入26.77億元,較去年同期增長39.27%;其中各種血液灌流器、吸附器產品實現銷售收入25.04億元,同比增長59.58%。實現歸屬於上市公司股東的淨利潤8.2億元,較去年同期增長87.91%;實現扣除非經常性損益的淨利潤7.79億元,同比增長90.46%。報告期內,公司整體毛利率爲80.78%,其中血液灌流器產品毛利率爲85.01%,保持強勁的盈利能力和市場競爭力。經營活動產生的現金流量淨額爲10.51億元,超出淨利潤2.37億元,收入和淨利潤的質量持續提高。向全體股東每10股派發現金紅利8元。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.